What it is
Epitalon (also spelled Epithalon or Epithalone) is a synthetic tetrapeptide with the sequence Ala-Glu-Asp-Gly. It is a short, defined fragment derived from Epithalamin, a natural pineal-gland extract studied by Professor Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology in Russia. The proposed headline mechanism is activation of telomerase, the enzyme that maintains the protective telomere caps on chromosomes, alongside support of pineal function and melatonin output.
Read that “proposed” carefully. Epitalon is one of the most hype-heavy peptides out there, and the gap between the claims and the verifiable evidence is wide.
What people use it for
People use it on a longevity and “anti-ageing” rationale: telomere maintenance, sleep and circadian support via the pineal/melatonin angle, and general vitality in older age. Sleep and subjective wellbeing are the more grounded reasons; the life-extension framing is where the evidence gets weakest.
Typical dose range
The standard research protocol that circulates is 10 mg per day for 10 to 20 consecutive days, run as a short course only 2 to 3 times per year rather than continuously. More conservative versions use around 5 mg daily for 10 days, twice a year. The pulsed, infrequent cycling is unusual among peptides and comes from the original Russian protocols rather than from dose-optimisation trials.
Treat these numbers as convention inherited from one research tradition, not as validated dosing. If reconstituting, get the concentration and dose right: Peptide Calculator - Reconstitution & Dosage | Buy Peptides UK
Half-life and frequency
The circulating half-life is very short, on the order of minutes; the peptide is cleared rapidly. The rationale offered for short pulsed courses is that the downstream effects (on telomerase, on the pineal) are claimed to outlast the molecule by a wide margin. Within a course, it is typically dosed once daily. Be aware this “brief signal, lasting effect” model is asserted more than it is firmly demonstrated in humans.
Reconstitution (typical)
Supplied as a lyophilised powder. Standard practice: bring the vial to room temperature, add bacteriostatic water gently down the vial wall, and swirl rather than shake to dissolve. Set your target concentration first so the per-dose volume is sensible, then calculate: Peptide Calculator - Reconstitution & Dosage | Buy Peptides UK
Storage
Keep the sealed lyophilised vial frozen at around -20 C, dark and dry, for long-term storage. After reconstitution, refrigerate at 2 to 8 C, keep out of light, and use within roughly 28 days. Do not freeze a reconstituted vial; freeze-thaw cycles damage the peptide. Because courses are short and infrequent, plan vial size so you are not storing reconstituted solution far past its window.
Common side effects
In the available reports, epitalon is generally described as well tolerated, with few side effects noted at the protocol doses. Most commonly mentioned:
- Injection-site reactions (redness, mild discomfort)
- Occasional drowsiness or changes in sleep, consistent with the melatonin-related rationale
Important honesty point: a clean side-effect profile in the literature partly reflects how little rigorous, independent safety monitoring has been done, not a guarantee of safety. “Few reported side effects” is not the same as “proven safe”, especially given the telomerase angle (see unknowns).
Stacking and co-solubility
Epitalon is frequently grouped with other Khavinson-type short peptides (for example Pinealon) in community protocols, again on tradition rather than controlled comparison. There is no human trial evidence showing a specific stack improves outcomes. As a practical matter, separately reconstituted peptides are usually dosed from their own vials rather than co-mixed, since each has its own stability behaviour. Keep expectations modest: stacking unproven peptides does not multiply a benefit that is itself not well established.
Evidence grade (human RCT / small human / animal-only / anecdote)
Weak overall, and this needs stating plainly.
- Cell and animal data: epitalon increased telomerase activity in human cell cultures in vitro and showed effects in animal models. This is the more concrete part, but it is preclinical.
- Human longevity claims: rest largely on observational cohort work from a single Russian research group (Khavinson and colleagues), including multi-decade elderly-cohort studies reporting reduced mortality. These reports are striking but are structured in ways Western reviewers cannot independently audit, were often published in Russian-language or low-impact venues, and have not been replicated by independent groups using modern standards.
- Western, independent, controlled trials: effectively absent. No Khavinson bioregulator has cleared a Phase 3 equivalent by Western regulatory standards.
- Most user-level benefit reports: anecdote.
So: animal-and-in-vitro for the mechanism, single-group and unaudited for the big human claims, and anecdote for most of what people repeat online. That is a fragile evidence base for a compound sold on the promise of longer life.
Honest unknowns
- Whether epitalon meaningfully extends human lifespan or healthspan is not established by independent, modern, controlled research.
- Activating telomerase is a double-edged idea. Telomerase is also a feature of many cancers, and the long-term oncological safety of deliberately upregulating it in humans is not known. This cuts directly against the “harmless longevity peptide” framing.
- Optimal dose, course length and cycling frequency are not validated; the popular protocol is inherited, not tested against alternatives.
- Non-prescription supply is unregulated, so actual contents, purity and dose accuracy vary, and the marketing around this compound tends to outrun the science.
Research use only. Not medical advice. 18+.